Morgan Stanley initiated coverage on Rocket Pharmaceuticals (RCKT) with an Overweight rating and a price target of $45.00 as the leader in the gene therapy prepares to enter a pivotal study in Q2/23 with its RP-A501, the first and best-in-class treatment for Danon disease.
BofA Securities initiated coverage on New Fortress Energy (NFE) with a Buy rating and a price target of $67.00. Shares gained more than 4% today.
Mizuho Securities initiated coverage on General Mills (GIS) with a Neutral rating and a price target of $75.00.
Cantor Fitzgerald initiated coverage on Beam Therapeutics Inc (BEAM) with an Overweight rating and a price target of $62.00. Shares surged more than 5% today.
Raymond James initiated coverage on Everest Re Group (RE) with an Outperform rating and a price target of $385.00.
Raymond James initiated coverage on Accolade Inc. (ACCD) with an Outperform rating and a price target of $15.00.
By Davit Kirakosyan
Want this type of news in real-time as it happens? Upgrade to StreetInsider.com Premium Here